Sign in
CompletedPhase 1/2

An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)

Key facts

Who runs it
JCR Pharmaceuticals Co., Ltd.
Where
Oakland, United StatesSee the siteAlso in 2 other countries, 5 sites
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
14 people enrolled
Started
28 Oct 2021
Ended
2 May 2025
Type of study
Interventional, 2 groups
Treatments tested
  • JR-171
Record updated
28 August 2025

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients who have completed the Part 2 of JR-171-101 study
  • A patient from whom written informed consent can be obtained. If the patient is aged under 18 years (20 years in case of Japan) at the time of assent or willingness to participate in the study cannot be confirmed due to MPS I-related intellectual disability, informed permission from the patient's legally acceptable representative (e.g., his/her parents or guardians) need to be obtained instead of his/her consent. Even in this case, written informed consent should be obtained from the patient, wherever possible
  • Female patient or male patient whose co-partners is of child-bearing potential agree to use a medically accepted, highly effective method of contraception, such as spermatocidal gel plus condom, an intrauterine device or oral contraceptives until one month after the final administration

Who cannot take part

  • Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of a serious drug allergy or hypersensitivity to any drugs
  • A patient who is unable to perform the study procedures, except for 6-minute walk test, neurocognitive testing, BVMT-R, HVLT-R, and T.O.V.A
  • Judged by the principal investigator or subinvestigator as being unable to undergo lumbar puncture, including those who have difficulties in taking a position for lumbar puncture due to joint contracture or those who are likely to experience difficulty breathing during the lumbar puncture process
  • Otherwise judged by the principal investigator or subinvestigator to be ineligible to participate in the study in consideration of patient's safety

Where in United States

Also in 2 other countries, 5 sites

  • UCSF Benioff Children's Hospital OaklandOakland, United States

About the trial

What the trial wants to find out

Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 (NCT04227600) for the treatment of MPS I

The 2 groups in the trial

  • Dose level 1Treatment being tested

    2.0 mg/kg/week

    Treatment: JR-171

  • Dose level 2Treatment being tested

    4.0 mg/kg/week

    Treatment: JR-171

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I
Record updated
28 August 2025